Family Medicine Doctors in Carlisle, IA Accepting Medicare
6 Family Medicine doctors found. Showing 1 - 6
 Marvin R. Huff, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2755 S. Gateway Drive, Carlisle, IA 50047 Phone: 515-358-7300 Fax: 515-358-7341 |
 Dr. Jennifer Mae Olson, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2755 S. Gateway Drive, Carlisle, IA 50047 Phone: 515-358-7300 Fax: 515-358-7341 |
Dr. Michael J Mccormick, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 125 School St, Po Box F, Carlisle, IA 50047 Phone: 515-989-3221 Fax: 515-989-4518 |
Catherine Alexandra Del Rosario, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2755 Gateway Dr, Carlisle, IA 50047 Phone: 515-358-7300 Fax: 515-358-7341 |
Joellen Heims, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2755 S. Gateway Drive, Carlisle, IA 50047 Phone: 515-358-7300 Fax: 515-358-7341 |
Marissa Pyle, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2755 Gateway Dr, Carlisle, IA 50047 Phone: 515-358-7300 Fax: 515-358-7341 |
News Archive
Dentists need to take a closer look at potential hazards of exposing patients to zinc
Dentists need to take a closer look at potential hazards of exposing patients to zinc, a common ingredient of many dental products, according to a report by Amar Patel, DDS, resident and colleagues at the University of Maryland Dental School in the March/April 2011 issue of the journal General Dentistry.
Mayo Clinic investigators discover potential diagnostic markers for bipolar I disorder
Mayo Clinic researchers have discovered a series of proteins that could be diagnostic markers to identify bipolar I disorder. If this discovery sample can be validated through replication these markers may help as a diagnostic tool for psychiatrists treating mood disorders.
Roche's new breast cancer drug Pertuzumab up for FDA review
U.S. health regulators, the Food and Drugs Administration (FDA) has granted a priority review for an experimental Roche breast cancer drug that in clinical trials added six months to the time before the disease worsened. Pertuzumab approval decision is due by June 8th this year. It could be used with Herceptin in HER2-positive patients. This was announced by Roche Holding AG's Genentech unit on Tuesday.
Mastectomy and reconstructive surgery may increase risk of becoming persistent drug users
Women who receive mastectomy and reconstructive surgery as part of breast cancer treatment may face the risk of developing persistent use of opioids and sedative-hypnotic drugs, according to data presented at the 2020 San Antonio Breast Cancer Symposium, held Dec. 8-11.
New discovery sheds light on how pancreatic cancer fuels its growth
A new discovery about pancreatic cancer sheds light on how the cancer fuels its growth and may help explain how promising cancer drugs work - and for whom they will fail.
› Verified 3 days ago